Veeva Systems is overvalued, with modest ~10% growth & high valuation multiples. Read why I recommend a sell rating on VEEV ...

KeyBanc lowered the firm’s price target on Veeva (VEEV) to $250 from $260 and keeps an Overweight rating on the shares. Into Q1 earnings, the ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Department of Pharmaceuticals (DoP) is set to commission a study to revamp the logistics value chain . (Image Source: Pixabay) Even as the pharma sector is still grappling with the uncertainty ...

Veeva Systems (VEEV) closed the latest trading day at $214.74, indicating a +0.5% change from the previous session's end. The stock's performance was ahead of the S&P 500's daily loss of 0.23%.

In its fourth quarter 2024 investor letter, TimesSquare Capital Management U.S. Focus Growth Strategy emphasized stocks such as Veeva Systems Inc. (NYSE:VEEV). Veeva Systems Inc. (NYSE:VEEV ...

Veeva Systems announced Veeva SiteVault CTMS, a clinical trial management system for research sites that’s integrated with SiteVault eISF and SiteVault eConsent to allow sites to comprehensively ...

Roni Kamhi, CEO BI Sky Global and COO of Innocan Pharma commented: "We are very pleased with our outstanding results and especially our strong revenue growth. At BI Sky Global we are clearly ...

COPENHAGEN, Denmark, March 31, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has submitted its New Drug Application (NDA) to the U.S. Food & Drug Administration ...

This a “game-changer” not only for the herbal medicine market but for the pharmaceuticals sector—and should encourage more initiatives like this that could give Filipinos a viable alternative to more ...